Clinical Neuroscience Solutions - Orlando

CNS Healthcare

Depression

Depressive Disorder

Post-Traumatic Stress Disorders

Human Influenza

Major Depressive Disorder

Traumatic Stress Disorders

Methylone

TNX-601

Baloxavir Marboxil

Roche

Tonix Pharmaceuticals

Transcend Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts.

* Part A is open-label and will enroll up to 15 participants with PTSD
* Part B is randomized (1:1), double-blind, placebo-controlled and will enroll up to 64 participants with PTSD

Eligible participants will enter a 3-week Treatment Period where they will receive methylone (or placebo in Part B) once weekly for 3 weeks (3 treatment sessions). Following the Treatment Period, participants will enter a 6-week Follow-up Period.

An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD

CNS Healthcare | Clinical Neuroscience Solutions - Orlando

Site insights

Work at this site?

Active trials

An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD (IMPACT-2)

Trial sponsors